![ESC/EAS recommendations for treatment of dyslipidemia in older adults.... | Download Scientific Diagram ESC/EAS recommendations for treatment of dyslipidemia in older adults.... | Download Scientific Diagram](https://www.researchgate.net/publication/316320929/figure/fig4/AS:962674863132677@1606530981401/ESC-EAS-recommendations-for-treatment-of-dyslipidemia-in-older-adults-From-ESC-EAS.gif)
ESC/EAS recommendations for treatment of dyslipidemia in older adults.... | Download Scientific Diagram
![2020 Lipid Guidelines Review - Part 3 - Links To And Excerpts From "The 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" - Tom Wade MD 2020 Lipid Guidelines Review - Part 3 - Links To And Excerpts From "The 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" - Tom Wade MD](https://www.tomwademd.net/wp-content/uploads/2020/01/fig8-5-e1580112545718.png)
2020 Lipid Guidelines Review - Part 3 - Links To And Excerpts From "The 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" - Tom Wade MD
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Nicholas Marston on Twitter: "ESC/EAS GL rec's LDL-C goal of <1 mmol/L (40 mg/dl) for subset of very high-risk ASCVD pts But is this supported by the data? We answered this by
![PDF] 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. | Semantic Scholar PDF] 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2677d05e0615fb7c44c784b83ad90687fe00d60d/12-Figure1-1.png)
PDF] 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. | Semantic Scholar
![Achievement of ESC/EAS lipid treatment goals with evolocumab in patients with type 2 diabetes: analyses of the Banting and Berson trials - Media Centre | EASD Achievement of ESC/EAS lipid treatment goals with evolocumab in patients with type 2 diabetes: analyses of the Banting and Berson trials - Media Centre | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/talks/939_251642/Slide1.jpg)
Achievement of ESC/EAS lipid treatment goals with evolocumab in patients with type 2 diabetes: analyses of the Banting and Berson trials - Media Centre | EASD
![The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society - PACE-CME The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society - PACE-CME](https://pace-cme.org/2019/09/12/the-2019-esc-eas-dyslipidemia-guidelines-from-the-point-of-view-of-the-european-atherosclerosis-society/images/The-2019-ESC-EAS-Dyslipidemia-Guidelines-from-the-point-of-view-of-the-European-Atherosclerosis-Society-2x.jpg)
The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society - PACE-CME
![2020 Lipid Guidelines Review - Part 3 - Links To And Excerpts From "The 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" - Tom Wade MD 2020 Lipid Guidelines Review - Part 3 - Links To And Excerpts From "The 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" - Tom Wade MD](https://www.tomwademd.net/wp-content/uploads/2020/01/fig1-10.png)